You are here: Home » News-IANS » Health-Medicine
Business Standard

New combo therapy found effective in kidney cancer patients

IANS  |  New York 

Combining an anti-agent, which blocks blood vessel formation, with an agent, has shown promising anti-activity in an early phase clinical trial in patients with advanced kidney who had not been previously treated, says a new study.

The findings of the study involving the combination of anti-agent -- axitinib (trade name Inlyta) - and the agent -- pembrolizumab (trade name Keytruda) - were published in the journal The Lancet Oncology.

The agent, pembrolizumab, is an immune checkpoint inhibitor that blocks a self-defence mechanism used by cells to evade attack and destruction by the body's immune cells.

"Our results are unprecedented. The combination doubled the efficacy of the drugs when used alone and the treatment was found to be tolerable," said of in Washington, DC, and

"Specifically, over 90 per cent of patients exhibited shrinkage and the was kept under control for a median of over 20 months," Atkins said.

The investigators started their phase-1 clinical trial of this combination in 2014 and enrolled 52 (the most common form of kidney cancer) patients who had not previously been treated for the

With this new combination therapy, shrinkage or stabilisation was better than that seen in patients taking just one of the two drugs alone, the researchers found.

Patients also had fewer liver abnormalities and less than those treated with other similar combination therapies, Atkins said.

"We think this combination could present a major advance in the as well as help define effective combinations of similar drugs for other cancers," Atkins said.



(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Sun, February 11 2018. 15:50 IST